This inventor holds 3 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 2 EPO patents. Top assignees: Ucb Biopharma Sprl, Ucbbiopharma Srl. Active years: 2018-2026.
Company Filing History:
Years Active: 2018-2026
Title: The Innovative Contributions of David Skolc
Introduction
David Skolc is a notable inventor based in Brussels, Belgium. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that act as positive allosteric modulators. With a total of 3 patents to his name, Skolc's work has the potential to impact the treatment of various diseases.
Latest Patents
Among his latest patents is the invention of a substituted tetrahydroisoquinoiline derivative, which serves as a D1 positive allosteric modulator. This compound is beneficial as a pharmaceutical agent for treating diseases where D1 receptors play a crucial role. Another significant patent involves tetrahydroisoquinoline derivatives, which are also recognized as positive allosteric modulators of D1, further emphasizing their potential in pharmaceutical applications.
Career Highlights
David Skolc has worked with prominent companies in the pharmaceutical industry, including UCB Biopharma Sprl and UCB Biopharma Srl. His experience in these organizations has allowed him to collaborate on innovative projects that advance medical science.
Collaborations
Some of his notable coworkers include Ali Ates and Anne Valade, who have contributed to his research and development efforts.
Conclusion
David Skolc's innovative work in the field of pharmaceuticals highlights his commitment to advancing medical treatments through his patented inventions. His contributions are paving the way for new therapeutic options in the healthcare industry.